<DOC>
	<DOCNO>NCT00004771</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate effect androgen suppression leuprolide androgen replacement testosterone enanthate muscle strength men Kennedy 's disease motor neuron disease .</brief_summary>
	<brief_title>Phase II Study Leuprolide Testosterone Men With Kennedy 's Disease Other Motor Neuron Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : All patient receive androgen suppression leuprolide acetate injection every 4 week 6 month , plus hormone replacement therapy testosterone enanthate injection every week 24 week .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Muscular Disorders , Atrophic</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Men age 18 motor neuron disease , i.e . : Xlinked spinal bulbar muscular atrophy ( Kennedy 's disease ) Confirmed androgen receptor , exon1 mutation genotype Amyotrophic lateral sclerosis Spinal muscular atrophy Significant muscle weakness manual muscle test No prisoner No mental disability</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>motor neuron disease</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>spinal bulbar muscular atrophy</keyword>
	<keyword>spinal muscular atrophy</keyword>
	<keyword>Kennedy 's Syndrome</keyword>
</DOC>